Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.95 EUR | +2.63% | +2.09% | +78.90% |
May. 16 | GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024 | CI |
Mar. 20 | Geneuro SA Announces Appointments of Board of Directors | CI |
Sales 2024 * | 28.2M 30.58M | Sales 2025 * | - | Capitalization | 57.71M 62.59M |
---|---|---|---|---|---|
Net income 2024 * | 1M 1.08M | Net income 2025 * | -26M -28.2M | EV / Sales 2024 * | 2.33 x |
Net Debt 2024 * | 7.9M 8.57M | Net Debt 2025 * | 34.9M 37.85M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
65
x | P/E ratio 2025 * |
-2.24
x | Employees | 17 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 73.25% |
1 day | +2.63% | ||
1 week | +2.09% | ||
1 month | +33.56% | ||
3 months | +54.76% | ||
6 months | +89.32% | ||
Current year | +78.90% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 05-12-31 | |
Hervé Perron
FOU | Founder | 66 | 05-12-31 |
Miguel Payró
DFI | Director of Finance/CFO | 62 | 15-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 21-05-26 | |
Michel Dubois
BRD | Director/Board Member | 81 | 08-07-15 |
Gordon Francis
BRD | Director/Board Member | 75 | 15-03-16 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 1.95 | +2.63% | 13,796 |
24-05-30 | 1.9 | -0.26% | 16,590 |
24-05-29 | 1.905 | -1.80% | 9,053 |
24-05-28 | 1.94 | +0.52% | 2,499 |
24-05-27 | 1.93 | +1.05% | 228 |
Real-time Euronext Paris, May 31, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+78.90% | 62.59M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- GNRO Stock